1Koopman M M,Bossuyt P M.Low molecular weight heparin for outpatient treatment of venous thromboembolism:safe,effective,and cost reducing?[J].Am J Med,2003,115(4):324-325.
2Massicottea P,Julian J A,Gent M,et al.An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children:the REVIVE trial[J].Thromb Res,2003,109(2-3):85-92.
3Boneu B.Low molecular weight heparins:Are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?[J].Thromb Res,2000,100(2):V113-V120.
4Goodman S G,Fitchett D,Armstrong P M,et al.Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein Ⅱb/Ⅲa inhibitor eptifibatide[J].Circulation,2003,107(2):238-244.
5Roffia M,Topolb E J.Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes[J].Eur Heart J,2004,25(3):190-198.
6James S,Armstrong P,Califf R,et al.Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes[J].Eur Heart J,2002,23(19):1538-1545.
7Prasad A,Mathew V,Holmes D R,et al.Current management of non-ST-segment-elevation acute coronary syndrome:reconciling the results of randomized controlled trials[J].Eur Heart J,2003,24(17):1544-1553.
8Gurfinkel E,Duronto E,Colorio C,et al.Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin(low molecular weight heparin)or unfractionated heparin[J].J Thromb Thrombol,1999,8(3):227-232.
